Treating AML: Current and Novel Approaches (ASH/LLS Webinar)
Acute myeloid leukemia (AML) is the most common acute leukemia in the United States and worldwide, but despite advances in the treatment of other blood cancers, the standard of care for most AML patients has changed very little in 40 years. The American Society of Hematology (ASH) has teamed up with The Leukemia & Lymphoma Society (LLS) through its “Beat AML” initiative to educate hematologists and other health care professionals about the importance of using advanced genomic technology to understand the genetic mutations in AML and identify targeted therapies to inhibit these mutations and more effectively treat the cancer. Tune in to the webinar on current and novel approaches to treating AML, featuring Ross Levine, MD, and Bernadette Cuello, NP, and learn more about LLS’s precision medicine Beat AML Master Trial, designed to test novel targeted therapies and change the treatment paradigm for patients diagnosed with AML.
Meeting Evaluations-2017 Translational Research in Training in Hematology Spring Course (Participants)
2017 Translational Research in Training in Hematology Spring Course (Participants)
Meeting Evaluations-2017 Clinical Research Training Institute Pre-Survey (Eligible Participants)
2017 Clinical Research Training Institute Pre-Survey (Eligible Participants)
Hematology 2016: CME/MOC Tests
Hematology 2016: CME/MOC Tests are two 25-question modules used to claim up to 40 hours of CME credit or ABIM MOC Points. Each test is worth 20 credits.